Greg Perry’s statement to the BioVision opening plenary 24 March 2013: The MPP aims to advance innovation, expand access to HIV medications and promote public health. We were created to be “a new business model for the future”, according to Phillipe Douste-Blazy, former minister of France and chair of UNITAID. … Read more
GENEVA, MARCH 2013: The Medicines Patent Pool has signed a licence with Shasun Pharmaceuticals and Gilead Sciences that will allow Shasun to produce the active ingredients of 5 key HIV medicines licensed to the MPP by Gilead Sciences for sale in the 100-112 countries where the majority of people living … Read more
GENÈVE, SUISSE : le Medicines Patent Pool annonce aujourd’hui la mise en place d’une collaboration avec ViiV Healthcare (partenariat entre GlaxoSmithKline, Pfizer et Shionogi) visant à améliorer l’accès aux médicaments indispensables pour traiter les enfants atteints du VIH. Leer este documento en español • Read this document in English 3,4 … Read more
GINEBRA, SUIZA: El Medicines Patent Pool (MPP) anuncia hoy la firma de un acuerdo de colaboración con ViiV Healthcare, una empresa conjunta de GlaxoSmithKline, Pfizer y Shionogi, tendiente a promover una mayor disponibilidad de medicamentos extremadamente necesarios para niños que viven con el VIH. Read this document in English • … Read more
GENEVA, SWITZERLAND: The Medicines Patent Pool (MPP) today announces the launch of a new collaboration with ViiV Healthcare – a joint venture of GlaxoSmithKline, Pfizer, and Shionogi – to facilitate greater availability of critically needed medicines for children living with HIV. There are 3.4 million children living with HIV worldwide. … Read more
GENEVA, 5 February 2013: The Medicines Patent Pool welcomes the recognition of its work by three key intergovernmental agencies in a new report exploring different strategies for access to and innovation on medical technologies in developing countries. Patents can be used “expressly to leverage public health outcomes” when licensed with … Read more